Related Experiment Video

Updated: Jun 18, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

Potassium channels: the 'master switch' of renal fibrosis?

Paolo Menè1, Nicola Pirozzi

  • 1Department of Molecular Medicine, Division of Nephrology, 'Sapienza' University of Rome, Rome, Italy. Paolo.Mene@uniroma1.it

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|December 1, 2009
PubMed

Insights

Targeting the intermediate/small-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) can prevent kidney fibrosis. Blocking K(Ca)3.1 inhibits renal fibroblast proliferation and reduces fibrotic markers in preclinical models.

Area of Science:

  • Nephrology
  • Cell Biology
  • Ion Channel Physiology

Background:

  • Progressive renal fibrosis, driven by interstitial fibroblast proliferation, is a key feature of chronic kidney disease.
  • The intermediate/small-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) is known to promote cell proliferation by regulating membrane potential and calcium influx.

Purpose of the Study:

  • To investigate the role of K(Ca)3.1 in renal fibroblast proliferation and the development of kidney fibrosis.
  • To determine if inhibiting K(Ca)3.1 could suppress renal fibrosis.

Main Methods:

  • Utilized murine renal fibroblasts and a mouse model of unilateral ureteral obstruction (UUO) to study K(Ca)3.1 function.
  • Assessed the effects of K(Ca)3.1 deficiency (KO mice) and pharmacological blockade (TRAM-34) on fibroblast proliferation and fibrotic markers.
  • Evaluated K(Ca)3.1 expression and its impact on renal damage, collagen deposition, and alpha-smooth muscle actin positive cells post-UUO.

Main Results:

  • Mitogens stimulated K(Ca)3.1 in renal fibroblasts via a MEK-dependent pathway.
  • Selective K(Ca)3.1 blockade inhibited fibroblast proliferation by inducing G0/G1 cell cycle arrest.
  • K(Ca)3.1 knockout mice exhibited reduced fibrotic markers, tubulointerstitial damage, and collagen deposition after UUO.
  • Pharmacological inhibition of K(Ca)3.1 with TRAM-34 attenuated UUO-induced renal fibrosis in mice and rats.

Conclusions:

  • K(Ca)3.1 plays a significant role in renal fibroblast proliferation and the fibrotic process.
  • Targeting K(Ca)3.1 presents a potential therapeutic strategy for mitigating fibrotic kidney disease.
  • K(Ca)3.1 inhibition suppressed key indicators of renal fibrosis in preclinical models.

More Related Videos

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique07:19

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique

Published on: February 7, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Mechanically-gated Ion Channels01:12

Mechanically-gated Ion Channels

Mechanically-gated ion channels are proteins found in eukaryotic and prokaryotic cell membranes that open in response to mechanical stress. Tension, compression, swelling, and shear stress can alter the conformation of the protein, opening a transmembrane channel that allows the passage of ions for signal transmission. In eukaryotes, mechanically-gated channels are distributed in several regions like the neurons, lungs, skin, bladder, and heart, where they play critical roles in numerous...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...